drugset
drugset / Trial / NCT05588609

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609 ↗

Phase 2 Terminated 13 enrolled Partner Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

Timeline

Start
2022-11-17
Primary completion
2025-07-03
Completion
2025-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Zenocutuzumab Monoclonal antibody 750 mg Intravenous
Background Abiraterone acetate Small molecule 1000 mg Oral
Background Afatinib Small molecule 40 mg Oral
Background Enzalutamide Other / unclassified 160 mg Oral

Indications

castration-resistant prostate carcinoma